Compare Sanofi SA (SNY) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Xpeng Inc - ADR — how do they compare? Sanofi SA trades at $43.12 (market cap $104.06B), while Xpeng Inc - ADR trades at $10.6 (market cap $10.34B). The key difference: Sanofi SA is far larger — about 10.1× Xpeng Inc - ADR's market cap, and Sanofi SA pays a 5.61% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| SNY | XPEV | |
|---|---|---|
Market Cap | $104.06B | $10.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $52.34 | $28.07 |
52-Week Low | $41.33 | $10.57 |
Enterprise Value | $124.09B | $12.92B |
Dividend Yield | 5.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
XPEV trades at $10.93, down 0.18% for the day, with a bearish technical signal from moving averages. The company reported a net loss of $1.14B in 2025 despite revenue growth to $76.72B, and recent quarterly earnings missed expectations. Positive developments include a $900M robotics unit funding at a $6.3B valuation and new model launches aimed at boosting deliveries.
The outlook remains cautious due to persistent losses and competitive pressures, but analyst consensus is bullish with a $19 price target. Key risks include execution challenges in EV and robotics segments, while institutional interest and AI-driven initiatives offer potential upside if profitability improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
